美国食品和药物管理局 (FDA) 授予Sanofi公司的50岁以上成人流感和COVID-19联合疫苗快速通道地位. FDA grants Fast Track status to Sanofi's combined flu and COVID-19 vaccine for adults over 50.

美国食品和药物管理局已授予赛诺菲公司的两种联合疫苗候选人快速通道指定,用于预防50岁及以上的个人感染流感和COVID-19. The FDA has granted Fast Track designation to two combination vaccine candidates from Sanofi for preventing influenza and COVID-19 in individuals aged 50 and over. 这些非MRNA疫苗结合了两种疾病的现有、经核准的疫苗,这些疫苗的功效很高。 These non-mRNA vaccines combine existing, approved vaccines for both diseases, which have shown high efficacy. 正在进行的临床试验正在评估他们的安全和免疫反应。 Ongoing clinical trials are assessing their safety and immune response.